38647-83-5

Usage

Uses

Used in Pharmaceutical Industry:
(4-Chlorophenyl)guanidine mononitrate is used as an antimicrobial agent for its ability to combat bacteria and fungi, playing a crucial role in the development of various pharmaceutical formulations.
Used in Agricultural Products:
In the agricultural sector, (4-Chlorophenyl)guanidine mononitrate is utilized as a component in the creation of products designed to protect crops from microbial infections, thereby enhancing crop health and yield.
Used in Medical Research:
(4-Chlorophenyl)guanidine mononitrate is studied for its potential therapeutic applications, particularly in the treatment of diseases such as tuberculosis and cancer, due to its antimicrobial and possible disease-fighting properties.

InChI:InChI=1/C7H8ClN3.HNO3/c8-5-1-3-6(4-2-5)11-7(9)10;2-1(3)4/h1-4H,(H4,9,10,11);(H,2,3,4)

Upstream product

• 420-04-2 CYANAMID 
• 106-47-8 4-chloro-aniline 

Downstream Products

• 79574-85-9 C₁₄H₁₃ClN₄S 
• 1215292-26-4 2-(4-chloroanilino)-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-one 
• 1383718-56-6 (rac)-2-((4-chlorophenyl)amino)-7-methyl-7,8-dihydroquinazolin-5(6H)-one 
• 1383718-68-0 (rac)-2-((4-chlorophenyl)amino)-7-ethyl-7,8-dihydroquinazolin-5(6H)-one 
• 1448633-60-0 (rac)-2-((4-chlorophenyl)amino)-7-propyl-7,8-dihydroquinazolin-5(6H)-one 
• 1383718-49-7 2-((4-chlorophenyl)amino)-7,8-dihydroquinazolin-5(6H)-one 
• 1383718-71-5 2-((4-chlorophenyl)amino)-7,7-dimethyl-7,8-dihydroquinazolin-5(6H)-one 
• 1383074-03-0 4-(1-methyl-1H-benzimidazol-2-yl)-N-(4-chlorophenyl)pyrimidin-2-amine 
• 79574-94-0 [4-(4-Chloro-phenylamino)-2-phenylamino-thiazol-5-yl]-phenyl-methanone 
• 677752-91-9 4-{4-[2-(4-chloro-phenylamino)-pyrimidin-4-yl]-benzenesulfonyl}-piperazine-1-carboxylic acid tert-butyl ester 
• 645-18-1 N-(4-chloro-phenyl)-6-methyl-[1,3,5]triazine-2,4-diamine 

Relevant academic research and scientific papers

7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones designed by a “cut and glue” strategy are dual aurora a/vegf-r kinase inhibitors

Although overexpression and hyperactivity of protein kinases are causative for a wide range of human cancers, protein kinase inhibitors currently approved as cancer drugs address only a limited number of these enzymes. To identify new chemotypes addressing alternative protein kinases, the basic structure of a known PLK1/VEGF-R2 inhibitor class was formally dissected and reassembled. The resulting 7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones were synthesized and proved to be dual inhibitors of Aurora A kinase and VEGF receptor kinases. Crystal structures of two representatives of the new chemotype in complex with Aurora A showed the ligand orientation in the ATP binding pocket and provided the basis for rational structural modifications. Congeners with attached sulfamide substituents retained Aurora A inhibitory activity. In vitro screening of two members of the new kinase inhibitor family against the cancer cell line panel of the National Cancer Institute (NCI) showed antiproliferative activity in the single-digit micromolar concentration range in the majority of the cell lines.

C-H activation at a bidentate ligand coordinated to palladium(II) - An electrophilic attack supported by an external base

2-(2-Phenylaminopyrimidin-4-yl)pyridines undergo C-H activation at the phenyl ring in the ortho position to the amine nitrogen atom when reacted with (PhCN)2PdCl2 and finally form N,N,C-coordinated palladium(II) complexes in high yields. Five differently substituted complexes were synthesized and characterized by spectroscopy and X-ray structure analysis. The reaction mechanism for the formation of these complexes was elucidated by kinetic experiments, which allowed the calculation of the activation parameters of the complex formation.

C-H activation at a bidentate ligand coordinated to palladium(II) - An electrophilic attack supported by an external base

2-(2-Phenylaminopyrimidin-4-yl)pyridines undergo C-H activation at the phenyl ring in the ortho position to the amine nitrogen atom when reacted with (PhCN)2PdCl2 and finally form N,N,C-coordinated palladium(II) complexes in high yields. Five differently substituted complexes were synthesized and characterized by spectroscopy and X-ray structure analysis. The reaction mechanism for the formation of these complexes was elucidated by kinetic experiments, which allowed the calculation of the activation parameters of the complex formation.

A novel series of potent and selective IKK2 inhibitors

A novel series of aminopyrimidine IKK2 inhibitors have been developed which show excellent in vitro inhibition of this enzyme and good selectivity over the IKK1 isoform. The relative potency and selectivity of these compounds has been rationalized using QSAR and structure-based modelling.

2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity

Following the identification through virtual screening of 4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-ylamines as moderately potent inhibitors of cyclin-dependent kinase-2 (CDK2), a CDK inhibitor analogue program was initiated. The first aims were to optimize potency and to evaluate the cellular mode of action of lead candidate molecules. Here the synthetic chemistry, the structure-guided design approach, and the structure-activity relationships (SARs) that led to the discovery of 2-anilino-4-(thiazol-5-yl)pyrimidine ATP-antagonistic CDK2 inhibitors, many with very low nM Kis against CDK2, are reported. Furthermore, X-ray crystal structures of four representative analogues from our chemical series in complex with CDK2 are presented, and these structures are used to rationalize the observed biochemical SARs. Finally results are reported that show, using the most potent CDK2 inhibitor compound from the current series, that the observed antiproliferative and proapoptotic effects are consistent with cellular CDK2 and CDK9 inhibition.

Anti-cancer compounds

The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.